financetom
Business
financetom
/
Business
/
Citigroup Positioned for Growth With Potential Catalysts Beyond Elections, UBS Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Citigroup Positioned for Growth With Potential Catalysts Beyond Elections, UBS Says
Nov 8, 2024 5:58 PM

12:46 PM EST, 11/05/2024 (MT Newswires) -- Citigroup ( C ) has "potential catalysts" extending beyond US election results, UBS Securities said in a note Tuesday, noting that a Trump win would be beneficial for the bank.

UBS believes that the strategies of either the incoming President through tariffs or government expenditure might lead to inflation. In such a scenario, the firm believes that the risk, both worldwide and within the country, might lean more towards fewer cuts than what the current market expectations, as indicated by forward curves globally, suggest.

Consequently, Citigroup's ( C ) designation as "liability sensitive" suggests that the market is inaccurately valuing it as a beneficiary from fewer cuts, according to the note.

"As investors grapple with the market consequences of various election scenarios, one thing seems to be market consensus: [Citigroup ( C )] should be a beneficiary of a Trump victory, especially given its lagged performance," UBS said in the note.

UBS sees steady revenue growth and operational improvements as key drivers for Citi. The bank's ability to meet its 4% to 5% revenue CAGR target in 2025 would be "positive" for its shares, UBS said.

"A continuation of "good" volatility in trading and further rebound in capital markets activity -- would clearly materially benefit [Citigroup ( C )]," according to the note.

Additionally, UBS projects "stable-to-higher net" interest income in 2025, estimating $54.1 billion, even amid potential rate declines globally.

UBS maintained a neutral rating on Citi's stock with a $71 price target.

Shares of Citigroup ( C ) were up 1.5% in recent trading.

Price: 63.28, Change: +0.93, Percent Change: +1.49

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
AbbVie Says EMA Committee Recommends Marketing Approval of Ovarian Cancer Therapy
AbbVie Says EMA Committee Recommends Marketing Approval of Ovarian Cancer Therapy
Sep 20, 2024
08:29 AM EDT, 09/20/2024 (MT Newswires) -- AbbVie ( ABBV ) said on Friday that the European Medicines Agency's advisory committee has recommended a marketing authorization for the company's ovarian cancer therapy, mirvetuximab soravtansine. The therapy is being developed as a treatment for adult patients with platinum-resistant and epithelial ovarian, fallopian tube or primary peritoneal cancer who have been treated...
AECOM Secures Spot in Wessex Water's $4.92 Billion Capital Delivery Framework
AECOM Secures Spot in Wessex Water's $4.92 Billion Capital Delivery Framework
Sep 20, 2024
07:31 AM EDT, 09/20/2024 (MT Newswires) -- AECOM ( ACM ) said Friday that it won the top spot in the design consultant lot of Wessex Water's new capital delivery framework that covers 3.7 billion pounds ($4.92 billion) of investments in South West England from 2025 to 2030. The company said its reappointment to the design consultant lot spans an...
Guyana launches tender for power plant, natural gas liquids facility
Guyana launches tender for power plant, natural gas liquids facility
Sep 20, 2024
By Kemol King GEORGETOWN, Sept 20 (Reuters) - Guyana on Friday issued a request for proposals to build a gas-fired power plant and a facility for processing natural gas liquids, projects to feed industrial customers from its mostly untapped offshore gas reserves. The nation of 800,000 people relies on heavy fuel imports to generate power and consumers face frequent outages...
Fortress Biotech Prices Registered Direct Offering, Private Placements; Shares Fall
Fortress Biotech Prices Registered Direct Offering, Private Placements; Shares Fall
Sep 20, 2024
12:13 PM EDT, 09/20/2024 (MT Newswires) -- Fortress Biotech ( FBIO ) said Friday it has entered into agreements to sell about 3.9 million shares, or pre-funded warrants in lieu thereof, at $1.65 per share to healthcare focused institutional investors. The firm said it will issue warrants to the investors to buy up to about 3.9 million shares, with an...
Copyright 2023-2026 - www.financetom.com All Rights Reserved